Roche's Asian partnering head looks to tap regional innovation
This article was originally published in Scrip
With an emerging biotech sector and increasing levels of innovation, Asia is viewed by Roche as an attractive source of projects for potential licensing, and the company is building up its regional operations in this area. Despite having been in his new job only a few days and the looming threat of an approaching typhoon, Roche Pharma Japan general manager and Asian regional head of Roche Pharma Partnering (RPP), Joe McCracken, took time to talk to Scrip's Asia editor Ian Haydock about the company's partnering strategy.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.